SPONSOR
InxMed (Shanghai) Co., Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2, Phase 3
NCT05827796 Phase 1, Phase 2
Recruiting
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Pancreatic Cancer
NCT07174908 Phase 3
Recruiting
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Non-Small Cell Lung Cancer